JP2022538338A5 - - Google Patents

Info

Publication number
JP2022538338A5
JP2022538338A5 JP2021577856A JP2021577856A JP2022538338A5 JP 2022538338 A5 JP2022538338 A5 JP 2022538338A5 JP 2021577856 A JP2021577856 A JP 2021577856A JP 2021577856 A JP2021577856 A JP 2021577856A JP 2022538338 A5 JP2022538338 A5 JP 2022538338A5
Authority
JP
Japan
Prior art keywords
rilpivirine
pharmaceutically acceptable
acceptable salt
less
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021577856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/068734 external-priority patent/WO2021001508A1/en
Publication of JP2022538338A publication Critical patent/JP2022538338A/ja
Publication of JP2022538338A5 publication Critical patent/JP2022538338A5/ja
Priority to JP2026018074A priority Critical patent/JP2026097815A/ja
Withdrawn legal-status Critical Current

Links

JP2021577856A 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 Withdrawn JP2022538338A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026018074A JP2026097815A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
US62/870,413 2019-07-03
PCT/EP2020/068734 WO2021001508A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv in pediatric patients with rilpivirine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026018074A Division JP2026097815A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Publications (2)

Publication Number Publication Date
JP2022538338A JP2022538338A (ja) 2022-09-01
JP2022538338A5 true JP2022538338A5 (enExample) 2023-07-11

Family

ID=71579550

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021577856A Withdrawn JP2022538338A (ja) 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
JP2021577871A Withdrawn JP2022538449A (ja) 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
JP2026018065A Pending JP2026097814A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
JP2026018074A Pending JP2026097815A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021577871A Withdrawn JP2022538449A (ja) 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
JP2026018065A Pending JP2026097814A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
JP2026018074A Pending JP2026097815A (ja) 2019-07-03 2026-02-05 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Country Status (14)

Country Link
US (3) US20210000823A1 (enExample)
EP (2) EP3993799A1 (enExample)
JP (4) JP2022538338A (enExample)
KR (2) KR20220028049A (enExample)
CN (2) CN114126655A (enExample)
AU (2) AU2020300818A1 (enExample)
BR (2) BR112021026916A2 (enExample)
CA (1) CA3144307A1 (enExample)
IL (1) IL289457A (enExample)
JO (1) JOP20210347A1 (enExample)
MA (2) MA56449A (enExample)
MX (2) MX2022000060A (enExample)
PH (1) PH12021553288A1 (enExample)
WO (2) WO2021001508A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
NZ610729A (en) * 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
EP4233846B1 (en) * 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
MA46563B1 (fr) * 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
RU2755710C2 (ru) * 2017-06-30 2021-09-20 Вайв Хелткер Компани Комбинация, ее применение и способы лечения с использованием указанной комбинации
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Similar Documents

Publication Publication Date Title
JP6196041B2 (ja) 大うつ病を有する患者において減量療法を提供する方法
Taha et al. Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection
JP2017514911A5 (enExample)
KR20260046169A (ko) Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼
US20190151307A1 (en) Methods of treating patients co-infected with a virus and tuberculosis
JP2022538449A5 (enExample)
AU2002332610B2 (en) Use of atazanavir in HIV therapy
JP2022514561A5 (enExample)
JP2020527570A (ja) 組み合わせ薬物療法
JP2020528409A5 (enExample)
AU2018239257B2 (en) HIV post-exposure prophylaxis
WO2008043829A2 (en) Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine
RU2022102380A (ru) Способы лечения инфекции, вызванной вич, у пациентов детского возраста с применением рилпивирина
CN106860464A (zh) 用于联合抗病毒治疗的药物组合物及应用
CN117858705A (zh) 使用抗病毒化合物和硝唑尼特进行治疗
Kobayashi et al. A case of under-dosing after raltegravir formulation change in an elderly patient treated for HIV
US20260048058A1 (en) Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19
US20250186443A1 (en) Valacyclovir and celecoxib in combination with nirmatrelvir and ritonavir for the treatment of covid-19
CA3113011C (en) Integrase inhibitors for the prevention of hiv
Francisco Data Released from Startmrk Study of Isentress Versus Efavirenz
CA3054822C (en) Hiv post-exposure prophylaxis
Bowersox ACTG 343: three drugs better than two for maintaining HIV suppression
US20230158020A1 (en) Method for treating RNA viral infections, including COVID-19 (SARS-CoV-2)
JP2019508399A (ja) 多くの治療を経験したｈｉｖ−１に感染した個体において使用するためのホステムサビル
EA049592B1 (ru) СПОСОБ ЛЕЧЕНИЯ РНК ВИРУСНЫХ ИНФЕКЦИЙ, В ТОМ ЧИСЛЕ COVID-19 (SARS-CoV-2)